替吉奥联合奥沙利铂二线治疗晚期胃癌的临床观察

S-1 plus oxaliplatin as a second line chemotherapy for patients with advanced gastric cancer

目的观察替吉奥联合奥沙利铂二线治疗晚期胃癌的临床疗效和安全性。方法一线治疗失败的22例晚期胃癌患者,采用替吉奥80 mg/m2,分2次口服,d1-14;奥沙利铂130 mg/m2,静脉滴注,d1;28 d为1个周期,至少完成2个周期。结果 22例均可评价疗效,其中完全缓解1例,部分缓解6例,稳定10例,进展5例,有效率为31.82%。不良反应主要为骨髓抑制,胃肠道反应及周围神经毒性,多为Ⅰ-Ⅱ级。结论替吉奥联合奥沙利铂方案对一线治疗失败的晚期胃癌疗效肯定,不良反应可以耐受,值得进一步研究应用。

Objective To evaluate the effect and toxicity of S - 1 combined with oxaliplatin as a second line chemotherapy regimen for patients with advanced gastric cancer. Methods Twenty - two patients with advanced gastric cancer who had failed in first - line chemotherapy were enrolled in this study. S - 1 was administered orally twice daily at the dose of 80mg/m^2 on dl - 14. Oxalipatin was administered at 130mg/m^2 in infusion on dl. Every 28 days was set as one cycle and at least 2 cycles were given. Results Twenty - two patients were evaluable for efficacy. The response rate was 31.82%, with 1 CR, 6 PR, 10 SD, and 5 PD. The main adverse effects included bone marrow suppression, gastrointestinal reaction, and peripheral neuropathy, most of time were degree Ⅰ - Ⅱ. Conclusion S - 1 combined with oxali- platin is effective as a secondary line regimen for patients with advanced gastric cancer. This protocol is active and well tolerated. Further clinical studies are warranted.